中性粒细胞与淋巴细胞比值对三阴性乳腺癌临床预后及与Ki - 67表达的影响

目的 探讨中性粒细胞与淋巴细胞比值（neutrophil to lymphocyte ratio，NLR）对三阴性乳腺癌的临床预后影响及与Ki - 67表达的关系。方法 回顾性分析2006年1月 - 2012年12月于我院乳腺外科住院治疗的134例三阴性乳腺癌患者。NLR最佳临床分界值采用ROC曲线确定，并依此分NLR＜2.64组和NLR≥2.64组。临床独立预后因素采用单因素和多因素Cox回归模型分析。术后生存时间和生存曲线比较采用Kaplan - Meier和log - rank方法。Ki - 67的表达采用免疫组织化学方法检测。结果 NLR是三阴性乳腺癌的独立预后因素，最佳临界值为2.64。NLR＜2.64组术后中位DFS为39.10月，中位OS为52.30月；NLR≥2.64组术后中位DFS为27.35月，中位OS为37.35月。2组术后DFS和OS比较，差异具有统计学意义（P＜0.05）。NLR低组伴Ki - 67表达阴性的三阴性患者术后中位DFS和OS生存时间显著高于其他情况。结论 NLR是三阴性乳腺癌的关键影响预后因素，具有重复性强、非侵袭性、方便实用等特性，可用于预测三阴性乳腺癌临床预后。     

Diterpenoids from the Roots of Agastache rugosa

从土藿香根中得到两个二萜化合物，藿香酚（２）及异藿香酚（３）。经光谱解析（ＩＲ，ＵＶ，ＨＲＭＳ及ＮＭＲ谱），确定它们的结构分别为１１，１４ｄｉｈｙｄｒｏｘｙ１２ｍｅｔｈｏｘｙ１９（４→３）ａｂｅｏａｂｉｅｔａ４，（１８），８，１１，１３ｔｅｔｒａｅｎ７ｏｎｅ（２）和１１，１４ｄｉｈｙｄｒｏｘｙ１２ｍｅｔｈｏｘｙ１９（４→３）ａｂｅｏａｂｉｅｔａ３，８，１１，１３ｔｅｔｒａｅｎ７ｏｎｅ（３）藿香酚（２）为一新的化合物，而异藿香酚（３）系首次从天然界分离得到，二者为一对异构体。     

石家庄地区汉族人群DIS80(pMCT118)位点VNTR基因频率分布调查

本文采用ＰＣＲ技术对石家庄地区２１６名无关个体ＤＩＳ８０（ｐＭＣＴ１１８）位点扩增片段长度多态性的等位基因频率进行调查。ＰＣＲ扩增产物采用聚丙烯酰胺凝胶电泳分型及溴化乙锭染色，共检出７０种基因型，２５个等位基因，其中以１８、２４、３０三个等位基因频率最高。将本文结果与日本人群在ＤＩＳ８０（ｐＭＣＴ１１８）位点多态性结果进行比较，石家庄地区汉族人群ＤＩＳ８０（ｐＭＣＴ１１８）位点基因频率分布符合ＨａｒｄｙＷｅｉｎｂｅｒｇ平衡定律，该位点非父排除率为０．７１，个体识别率为０．９，杂合度为０．８５。     

输卵管积水造口术对体外受精与胚胎移植的影响

【目的】探讨在体外受精与胚胎移植 (IVF ET)之前输卵管积水患者行输卵管造口术对IVF ET治疗效果的影响。【方法】回顾分析 1999年 2月至 2 0 0 1年 1月因女性输卵管因素不孕行IVF ET治疗的 90 8个周期的资料。按输卵管积水患者在IVF ET前是否治疗分 3组 ,A组 :输卵管积水未手术治疗行IVF ET 2 3个周期 ,B组 :在IVF ET之前行输卵管积水造口术 (腹腔镜下或开腹 ) 2 2个周期 ,C组 :对照组 (输卵管阻塞 ,未发现输卵管积水 ) 86 3个周期。【结果】A组、B组、C组的IVF ET的种植率分别为 9 7%、17 9%、16 7% ,临床妊娠率分别为 2 1 7%、4 0 9%、39 2 %。A组的种植率及临床妊娠率比其它组低 ,经 χ2 检验 ,有统计学意义。【结论】输卵管积水未治疗行IVF ET的种植率及临床妊娠率较低 ,但在IVF ET之前行输卵管造口术可改善IVF ET的种植率及临床妊娠率     

Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer.

PURPOSE: To delineate gene expression patterns and profile changes in metastatic tumor biopsies at baseline and 1 month after treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib in patients with metastatic breast cancer. EXPERIMENTAL DESIGN: Patients were treated with 150 mg of oral erlotinib daily. Gene expression profiles were measured with Affymetrix U133A GeneChip and immunohistochemistry was used to validate microarray findings. RESULTS: Estrogen receptor (ER) status by immunohistochemistry is nearly coincided with the two major expression clusters determined by expression of genes using unsupervised hierarchical clustering analysis. One of 10 patients had an EGFR-positive tumor detected by both microarray and immunohistochemistry. In this tumor, tissue inhibitor of metalloproteinases-3 and collagen type 1 alpha 2, which are the EGF-down-regulated growth repressors, were significantly increased by erlotinib. Gene changes in EGFR-negative tumors are those of G-protein-linked and cell surface receptor-linked signaling. Gene ontology comparison analysis pretreatment and posttreatment in EGFR-negative tumors revealed biological process categories that have more genes differentially expressed than expected by chance. Among 495 gene ontology categories, the significant differed gene ontology groups include G-protein-coupled receptor protein signaling (34 genes, P = 0.002) and cell surface receptor-linked signal transduction (74 genes, P = 0.007). CONCLUSIONS: ER status reflects the major difference in gene expression pattern in metastatic breast cancer. Erlotinib had effects on genes of EGFR signaling pathway in the EGFR-positive tumor and on gene ontology biological process categories or genes that have function in signal transduction in EGFR-negative tumors.